Empagliflozin - CAS 864070-44-0
Catalog number: 864070-44-0
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
Molecular Weight:
Empagliflozin is a potent and selective SGLT-2 inhibitor with IC50 of 3.1 nM, exhibits >300-fold selectivity over SGLT-1, 4, 5 and 6.
BI10773; BI-10773; BI 10773; CE0108; CS0940; PB23119; VA10802; AJ93046; Empagliflozin; trade name Jardiance.
Canonical SMILES:
1.Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus: Systematic review and network meta-analysis.
Zaccardi F1,2, Webb DR1,2, Htike ZZ1,2, Youssef D1,2, Khunti K1,2, Davies MJ1,2. Diabetes Obes Metab. 2016 Apr 5. doi: 10.1111/dom.12670. [Epub ahead of print]
AIMS: To assess the comparative efficacy and safety of SGLT2 inhibitors in adults with type 2 diabetes.
2.Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial.
Tanaka A1, Inoue T2, Kitakaze M3, Oyama J4, Sata M5, Taguchi I6, Shimizu W7, Watada H8, Tomiyama H9, Ako J10, Sakata Y11, Anzai T12, Uematsu M13, Suzuki M14, Eguchi K15, Yamashina A9, Saito Y16, Sato Y17, Ueda S18, Murohara T19, Node K20. Cardiovasc Diabetol. 2016 Apr 4;15(1):57. doi: 10.1186/s12933-016-0381-x.
BACKGROUND: Because type 2 diabetes mellitus is associated strongly with an increased risk of cardiovascular diseases, the number of patients with diabetes with chronic heart failure is increasing steadily. However, clinical evidence of therapeutic strategies in such patients is still lacking. A recent randomized, placebo-controlled trial in patients with type 2 diabetes with high cardiovascular risk demonstrated that the SGLT2 inhibitor, empagliflozin, reduced the incidence of hospitalization for heart failure. Because SGLT2 inhibitors cause a reduction in body weight and blood pressure in addition to improving glycemic control, they have the potential to exert beneficial effects on the clinical pathophysiology of heart failure. The aim of the ongoing CANDLE trial is to test the safety and non-inferiority of canagliflozin, another SGLT2 inhibitor, compared with glimepiride, a sulfonylurea agent, in patients with type 2 diabetes mellitus and chronic heart failure.
3.Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes.
Kohler S1, Salsali A2, Hantel S3, Kaspers S4, Woerle HJ4, Kim G4, Broedl UC4. Clin Ther. 2016 Apr 13. pii: S0149-2918(16)30168-0. doi: 10.1016/j.clinthera.2016.03.031. [Epub ahead of print]
PURPOSE: The aim of this analysis was to establish the safety profile and tolerability of empagliflozin in patients with type 2 diabetes mellitus (T2DM) according to pooled data from several clinical trials.
4.Empagliflozin/Linagliptin: Combination therapy in patients with type 2 diabetes.
Tan X1, Hu J2. Ann Endocrinol (Paris). 2016 Apr 6. pii: S0003-4266(15)01131-2. doi: 10.1016/j.ando.2015.11.003. [Epub ahead of print]
Glyxambi® (empagliflozin/linagliptin) is a fixed-dose, once-daily tablet combining a sodium glucose co-transporter-2 (SGLT2) inhibitor with a dipeptidyl peptidase-4 (DPP-4) inhibitor. Glyxambi® is served as an adjuvant to diet and exercise to improve glycemic control in adults with type 2 diabetes when both empagliflozin and linagliptin are appropriate treatments. Glyxambi® combines 10mg or 25mg empagliflozin with 5mg linagliptin, with different, complementary mechanisms of action to improve glycemic control in patients with type 2 diabetes. Empagliflozin removes glucose through the urine by blocking blood glucose re-absorption in the kidney, and linagliptin exerts glucose-lowering activity by increasing hormones that stimulate the pancreas to produce more insulin and decreasing the levels of glucagon in the circulation. In addition, this combination therapy modestly reduces body weight and blood pressure without significant safety issues.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related SGLT Products

JNJ-39933673 hemihydrate
(CAS: 1404307-42-1)

TA-1887 is a selective Sodium Glucose Cotransporter 2 Inhibitor with pronounced antihyperglycemic effects in high-fat diet-fed KK (HF-KK) mice. It may be used f...

CAS 761423-87-4 Ipragliflozin

(CAS: 761423-87-4)

Ipragliflozin is a highly potent and selective SGLT2 inhibitor and has little and NO potency for SGLT1/3/4/5/6.

CAS 1201913-82-7 Tofogliflozin hydrate

Tofogliflozin hydrate
(CAS: 1201913-82-7)

Tofogliflozin(CSG-452) hydrate is a potent and highly specific sodium/glucose cotransporter 2(SGLT2) inhibitor with Ki values of 2.9, 14.9, and 6.4 nM for human...

CAS 1018899-04-1 LX-4211

(CAS: 1018899-04-1)

LX-4211 is a potent dual SGLT2/1 inhibitor; Antidiabetic agents.

CAS 60-81-1 Phlorizin

(CAS: 60-81-1)

Phlorizin is a 2'-glucoside of phloretin. It belongs to the group of dihydrochalcones, a type of flavonoids.

CAS 864070-44-0 Empagliflozin

(CAS: 864070-44-0)

Empagliflozin is a potent and selective SGLT-2 inhibitor with IC50 of 3.1 nM, exhibits >300-fold selectivity over SGLT-1, 4, 5 and 6.

CAS 1118567-05-7 EGT1442

(CAS: 1118567-05-7)

EGT1442 is a potent and selective SGLT2 inhibitor with IC50 value of 5.6 μM /2 nM in SGLT1 /SGLT2 respectively. It significantly prolonged the median survival o...

CAS 928672-86-0 Canagliflozin hemihydrate

Canagliflozin hemihydrate
(CAS: 928672-86-0)

Canagliflozin hemihydrate is a highly potent and selective inhibitor of subtype 2 sodium-glucose transport protein (SGLT2), which is responsible for at least 90...

Chemical Structure

CAS 864070-44-0 Empagliflozin

Quick Inquiry

Verification code

Featured Items